Blog
GLP-1 News & Updates
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
European Panel Backs Wegovy HD: Single-Dose 7.2mg Pen Moves Closer to EU Approval
EMA's CHMP recommends approval of Wegovy 7.2mg in convenient single-dose pen format, bringing 20.7% weight loss results to European patients by Q3 2026.
The DoseTrumpRx Launches with Historic $350 GLP-1 Pricing, Transforming Access
Government platform TrumpRx launched in February with GLP-1 drugs at $150-350/month, slashing costs 75% and expanding Medicare coverage for obesity for the first time.
The DoseFDA Issues 30 Warning Letters to Telehealth Firms for Misleading GLP-1 Claims
FDA escalates enforcement against telehealth companies marketing compounded GLP-1 drugs as identical to approved medications like Wegovy and Zepbound.
The DoseScientists Find Way to Extend GLP-1 Weight Loss, Break Drug Plateaus
NIH study reveals cellular mechanism behind GLP-1 weight loss plateaus and shows existing drug roflumilast could extend semaglutide effects, reducing injection frequency.
The DoseBariatric Surgery Plunges 34% as GLP-1 Drugs Surge 140% in Historic Shift
New JAMA Surgery study reveals dramatic shift in obesity treatment as GLP-1 prescriptions more than double while bariatric surgeries fall to lowest levels since 2020.
The DoseFDA Demands Post-Approval Safety Studies for New GLP-1 Pill Foundayo
FDA requests extensive safety studies for Eli Lilly's newly approved Foundayo (orforglipron) due to limited long-term data on the first small-molecule GLP-1 weight loss pill.
The DoseFDA Approves Wegovy HD: Highest-Dose GLP-1 Delivers Record 21% Weight Loss
FDA approved 7.2mg semaglutide injection in record 54 days, delivering 20.7% average weight loss - the most effective obesity treatment ever approved.
The DoseGLP-1 Drugs May Prevent Cancer from Spreading, Major Study Finds
Cleveland Clinic study of 10,000+ cancer patients shows GLP-1 drugs like Wegovy and Zepbound reduced risk of metastatic progression by up to 45%, especially in breast cancer.
The DoseWegovy Pill Now Available: First GLP-1 Oral Weight Loss Drug Hits US Market
Novo Nordisk officially launches Wegovy pill with $149 cash pricing, becoming the first oral GLP-1 drug for weight loss available in US pharmacies nationwide.
The DoseRetatrutide Shows Record 28% Weight Loss in Breakthrough Phase 3 Trial
Eli Lilly's experimental triple-agonist retatrutide delivered up to 70 pounds weight loss in Phase 3 trial, matching bariatric surgery outcomes and setting new benchmark for obesity medications.
The DoseCMS BALANCE Model Launches This Month: Medicaid GLP-1 Coverage Expands
CMS's voluntary BALANCE Model begins expanding Medicaid GLP-1 coverage this month, with Medicare Bridge program following in July at $50/month.
The DoseOral GLP-1 Drugs Target Brain's Reward Center for First Time, NIH Study Finds
NIH-funded study reveals small-molecule GLP-1 drugs like orforglipron penetrate deeper into the brain to suppress pleasure-based eating by targeting the central amygdala.